查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1947898

人工智慧疫苗研发市场分析及预测（至2035年）：按类型、产品类型、服务、技术、组件、应用、最终用户、研发阶段、部署类型和功能划分

AI for Vaccine Development Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, End User, Stage, Deployment, Functionality
出版日期: | 出版商: Global Insight Services | 英文 340 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计到2034年，人工智慧在疫苗研发领域的市场规模将从2024年的488亿美元成长至4,496亿美元，复合年增长率约为29.4%。该市场涵盖人工智慧技术在疫苗研究、设计和生产的应用。人工智慧透过分析大量资料集、预测病原体结构和优化临床试验，加速疫苗研发进程。对新兴疾病的快速反应需求以及人工智慧在缩短疫苗研发时间和降低成本方面的高效性，是推动市场成长的主要因素。关键趋势包括用于抗原发现和个人化疫苗设计的人工智慧平台，这反映了精准医疗的发展趋势。

人工智慧在疫苗研发领域的市场正经历显着成长，这主要得益于市场对创新疫苗解决方案的强劲需求。在该市场中，机器学习演算法表现最为突出，凭藉其先进的预测模型和数据分析能力，加速了疫苗研发进程。自然语言处理工具紧随其后，能够帮助处理大量的科学文献。人工智慧在临床试验模拟的应用也日益普及，有助于优化试验设计和病患招募策略。同时，人工智慧驱动的药物发现领域也取得了显着进展，利用深度学习更有效率地识别潜在候选疫苗。基于人工智慧的诊断工具正成为早期检测和监测疫苗有效性的关键组成部分。随着产业的不断发展，人工智慧开发者与製药公司之间日益密切的合作有望促进创新，并加速有效疫苗的上市进程。

市场区隔
类型 机器学习、深度学习、自然语言处理
产品 AI平台、AI工具、AI软体
服务 咨询、实施、支援和维护
科技 云端部署、本地部署、混合部署
成分 硬体、软体和服务
应用 药物发现、临床试验、疫苗生产、预测分析
最终用户 製药公司、生技公司、研究机构、受託研究机构（CRO）
发展阶段 临床前、临床、核准、上市后
实施表格 云端、本地部署、混合部署
功能 数据分析、自动化报告和预测建模

人工智慧在疫苗研发领域的市场份额正经历着动态变化，主要企业透过策略定价和创新产品推出不断巩固其市场地位。精准医疗的兴起和疫苗生产速度的加快推动了人工智慧技术的应用。新兴企业也纷纷涌入市场，利用尖端演算法优化疫苗效力。科技公司与大型製药公司之间的合作进一步推动了这一趋势，双方旨在充分发挥人工智慧在药物发现和研发方面的潜力。竞争基准分析显示，儘管大型科技公司引领人工智慧整合的步伐，但生技公司也迅速跟进。监管，尤其是在北美和欧洲的监管，对塑造市场动态至关重要，以确保疫苗的安全性和有效性符合标准。这些监管措施透过强制遵守严格的通讯协定来鼓励创新。随着人工智慧不断革新疫苗研发，在研发投入增加和技术进步的推动下，市场预计将迎来强劲成长。

主要趋势和驱动因素：

由于多项关键趋势和驱动因素，人工智慧在疫苗研发领域的市场正经历显着成长。人工智慧融入药物发现流程，加速了疫苗研发进程。机器学习演算法优化了候选疫苗的选择，降低了成本并提高了疫苗的有效性。这项技术进步正在重塑传统的研发模式，使人们能够快速应对新的健康威胁。此外，全球对疫情预防的日益重视也推动了对人工智慧疫苗研发的投资。各国政府和私营部门都在优先研发快速有效的疫苗，以遏止未来的疫情爆发。生物技术和人工智慧公司之间不断增加的资金投入和合作正在促进创新，这种协同效应对于应对复杂的生物学挑战至关重要。此外，随着个人化医疗需求的增长，人工智慧正被用于开发针对个人基因谱量身定制的疫苗。这一趋势正在提高疫苗接种策略的准确性和有效性。人工智慧在预测病毒变异方面的能力也蕴藏着许多机会，能够确保疫苗对不断演变的病原体的有效性。随着这些趋势和驱动因素的不断发展，人工智慧在疫苗研发领域的市场预计将持续成长。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 机器学习
    • 深度学习
    • 自然语言处理
  • 市场规模及预测：依产品划分
    • 人工智慧平台
    • 人工智慧工具
    • 人工智慧软体
  • 市场规模及预测：依服务划分
    • 咨询
    • 执行
    • 支援与维护
  • 市场规模及预测：依技术划分
    • 基于云端的
    • 本地部署
    • 杂交种
  • 市场规模及预测：依组件划分
    • 硬体
    • 软体
    • 服务
  • 市场规模及预测：依应用领域划分
    • 药物发现
    • 临床试验
    • 疫苗生产
    • 预测分析
  • 市场规模及预测：依最终用户划分
    • 製药公司
    • 生技公司
    • 研究所
    • 合约研究机构
  • 市场规模及预测：依阶段划分
    • 临床前阶段
    • 临床领域
    • 核准
    • 售后
  • 市场规模及预测：依发展状况
    • 云
    • 本地部署
    • 杂交种
  • 市场规模及预测：依功能划分
    • 数据分析
    • 自动报告
    • 预测建模

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章：公司简介

  • Benevolent AI
  • Exscientia
  • Atomwise
  • Insilico Medicine
  • Recursion Pharmaceuticals
  • Xtal Pi
  • Valo Health
  • Cyclica
  • Deep Genomics
  • Healx
  • Bio Symetrics
  • Schrodinger
  • Verge Genomics
  • Peptilogics
  • Revive Med
  • Two XAR
  • Numerate
  • Inveni AI
  • Owkin
  • Lantern Pharma

第九章：关于我们

简介目录
Product Code: GIS32842

AI for Vaccine Development Market is anticipated to expand from $48.8 billion in 2024 to $449.6 billion by 2034, growing at a CAGR of approximately 29.4%. The AI for Vaccine Development Market encompasses the integration of artificial intelligence technologies in the research, design, and production of vaccines. AI accelerates vaccine discovery by analyzing vast datasets, predicting pathogen structures, and optimizing clinical trials. The market is driven by the need for rapid response to emerging diseases and the efficiency of AI in reducing time and cost in vaccine development. Key trends include AI-driven platforms for antigen discovery and personalized vaccine design, reflecting a shift towards precision medicine.

The AI for Vaccine Development Market is experiencing significant growth, primarily driven by the surge in demand for innovative vaccine solutions. Within this market, the machine learning algorithms segment is the top performer, offering advanced predictive models and data analysis capabilities that accelerate vaccine research. Natural language processing tools, which assist in processing vast amounts of scientific literature, follow as the second highest-performing segment. The integration of AI in clinical trial simulations is also gaining momentum, enhancing trial design and patient recruitment strategies. Meanwhile, the AI-driven drug discovery sub-segment is making substantial strides, leveraging deep learning to identify potential vaccine candidates more efficiently. AI-based diagnostic tools are emerging as a vital component, supporting early detection and monitoring of vaccine efficacy. As the industry evolves, the collaboration between AI developers and pharmaceutical companies is expected to intensify, fostering innovation and expediting the delivery of effective vaccines to the market.

Market Segmentation
TypeMachine Learning, Deep Learning, Natural Language Processing
ProductAI Platforms, AI Tools, AI Software
ServicesConsulting, Implementation, Support and Maintenance
TechnologyCloud-based, On-premise, Hybrid
ComponentHardware, Software, Services
ApplicationDrug Discovery, Clinical Trials, Vaccine Manufacturing, Predictive Analytics
End UserPharmaceutical Companies, Biotechnology Companies, Research Institutes, Contract Research Organizations
StagePre-clinical, Clinical, Approval, Post-marketing
DeploymentCloud, On-premise, Hybrid
FunctionalityData Analysis, Automated Reporting, Predictive Modeling

AI for vaccine development is witnessing a dynamic shift in market share, with leading companies enhancing their foothold through strategic pricing and innovative product launches. The focus on precision medicine and accelerated vaccine production timelines has spurred the adoption of AI technologies. Emerging players are also entering the market, leveraging cutting-edge algorithms to optimize vaccine efficacy. This trend is further supported by collaborations between tech firms and pharmaceutical giants, aiming to harness AI's potential in drug discovery and development. Competitive benchmarking reveals that major tech companies are setting the pace in AI integration, while biotech firms are rapidly catching up. Regulatory influences, particularly in North America and Europe, are pivotal in shaping market dynamics, ensuring safety and efficacy standards are met. These regulations also drive innovation by necessitating compliance with stringent protocols. As AI continues to revolutionize vaccine development, the market is poised for robust growth, with increased investment in R&D and technological advancements.

Geographical Overview:

The AI for Vaccine Development Market is witnessing notable growth across various regions, each presenting unique opportunities. North America leads the market, propelled by advanced AI technologies and substantial investments in healthcare research. The presence of major pharmaceutical companies and AI startups further accelerates growth. Europe follows, with strong governmental support for AI in healthcare, fostering a dynamic ecosystem for vaccine development. The region's focus on innovation and collaboration enhances its market potential. In the Asia Pacific, rapid technological advancements and increasing healthcare investments drive market expansion. Countries like China and India are emerging as key players, leveraging AI to expedite vaccine research and development. Latin America and the Middle East & Africa are burgeoning markets with significant opportunities. In Latin America, increasing public and private sector investments in AI are catalyzing growth. Meanwhile, the Middle East & Africa are recognizing AI's potential to revolutionize vaccine development, thereby boosting their healthcare sectors.

The AI for Vaccine Development Market is being intricately shaped by global tariff impacts and geopolitical risks, particularly in East Asia. Japan and South Korea, reliant on advanced AI technologies, are adapting to US-China trade tensions by enhancing domestic AI capabilities and fostering regional collaborations. China's focus on self-sufficiency is accelerating its AI innovation, while Taiwan's semiconductor prowess remains pivotal yet vulnerable to geopolitical pressures. The parent market for AI in healthcare is robust, driven by technological advancements and increased healthcare investments. By 2035, the market is poised for substantial growth, contingent on resilient supply chains and strategic partnerships. Additionally, Middle East conflicts could disrupt global supply chains and elevate energy prices, influencing operational costs and strategic planning in these nations.

Key Trends and Drivers:

The AI for Vaccine Development Market is experiencing remarkable growth due to several pivotal trends and drivers. The integration of artificial intelligence in drug discovery processes is accelerating vaccine development timelines. Machine learning algorithms are optimizing candidate selection, thereby reducing costs and improving efficacy. This technological advancement is reshaping traditional R&D frameworks, enabling rapid responses to emerging health threats. Moreover, the global emphasis on pandemic preparedness is driving investments in AI-driven vaccine research. Governments and private sectors are prioritizing swift and effective vaccine development to mitigate future outbreaks. Increased funding and collaboration between biotech firms and AI companies are fostering innovation. This synergy is crucial in addressing complex biological challenges. Additionally, the demand for personalized medicine is propelling the use of AI in tailoring vaccines to individual genetic profiles. This trend is enhancing the precision and effectiveness of immunization strategies. Opportunities abound in expanding AI capabilities to predict viral mutations, ensuring vaccines remain effective against evolving pathogens. The AI for Vaccine Development Market is poised for sustained growth as these trends and drivers continue to evolve.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Component
  • 2.6 Key Market Highlights by Application
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Stage
  • 2.9 Key Market Highlights by Deployment
  • 2.10 Key Market Highlights by Functionality

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Machine Learning
    • 4.1.2 Deep Learning
    • 4.1.3 Natural Language Processing
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 AI Platforms
    • 4.2.2 AI Tools
    • 4.2.3 AI Software
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Consulting
    • 4.3.2 Implementation
    • 4.3.3 Support and Maintenance
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Cloud-based
    • 4.4.2 On-premise
    • 4.4.3 Hybrid
  • 4.5 Market Size & Forecast by Component (2020-2035)
    • 4.5.1 Hardware
    • 4.5.2 Software
    • 4.5.3 Services
  • 4.6 Market Size & Forecast by Application (2020-2035)
    • 4.6.1 Drug Discovery
    • 4.6.2 Clinical Trials
    • 4.6.3 Vaccine Manufacturing
    • 4.6.4 Predictive Analytics
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Pharmaceutical Companies
    • 4.7.2 Biotechnology Companies
    • 4.7.3 Research Institutes
    • 4.7.4 Contract Research Organizations
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Pre-clinical
    • 4.8.2 Clinical
    • 4.8.3 Approval
    • 4.8.4 Post-marketing
  • 4.9 Market Size & Forecast by Deployment (2020-2035)
    • 4.9.1 Cloud
    • 4.9.2 On-premise
    • 4.9.3 Hybrid
  • 4.10 Market Size & Forecast by Functionality (2020-2035)
    • 4.10.1 Data Analysis
    • 4.10.2 Automated Reporting
    • 4.10.3 Predictive Modeling

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Component
      • 5.2.1.6 Application
      • 5.2.1.7 End User
      • 5.2.1.8 Stage
      • 5.2.1.9 Deployment
      • 5.2.1.10 Functionality
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Component
      • 5.2.2.6 Application
      • 5.2.2.7 End User
      • 5.2.2.8 Stage
      • 5.2.2.9 Deployment
      • 5.2.2.10 Functionality
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Component
      • 5.2.3.6 Application
      • 5.2.3.7 End User
      • 5.2.3.8 Stage
      • 5.2.3.9 Deployment
      • 5.2.3.10 Functionality
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Component
      • 5.3.1.6 Application
      • 5.3.1.7 End User
      • 5.3.1.8 Stage
      • 5.3.1.9 Deployment
      • 5.3.1.10 Functionality
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Component
      • 5.3.2.6 Application
      • 5.3.2.7 End User
      • 5.3.2.8 Stage
      • 5.3.2.9 Deployment
      • 5.3.2.10 Functionality
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Component
      • 5.3.3.6 Application
      • 5.3.3.7 End User
      • 5.3.3.8 Stage
      • 5.3.3.9 Deployment
      • 5.3.3.10 Functionality
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Component
      • 5.4.1.6 Application
      • 5.4.1.7 End User
      • 5.4.1.8 Stage
      • 5.4.1.9 Deployment
      • 5.4.1.10 Functionality
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Component
      • 5.4.2.6 Application
      • 5.4.2.7 End User
      • 5.4.2.8 Stage
      • 5.4.2.9 Deployment
      • 5.4.2.10 Functionality
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Component
      • 5.4.3.6 Application
      • 5.4.3.7 End User
      • 5.4.3.8 Stage
      • 5.4.3.9 Deployment
      • 5.4.3.10 Functionality
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Component
      • 5.4.4.6 Application
      • 5.4.4.7 End User
      • 5.4.4.8 Stage
      • 5.4.4.9 Deployment
      • 5.4.4.10 Functionality
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Component
      • 5.4.5.6 Application
      • 5.4.5.7 End User
      • 5.4.5.8 Stage
      • 5.4.5.9 Deployment
      • 5.4.5.10 Functionality
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Component
      • 5.4.6.6 Application
      • 5.4.6.7 End User
      • 5.4.6.8 Stage
      • 5.4.6.9 Deployment
      • 5.4.6.10 Functionality
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Component
      • 5.4.7.6 Application
      • 5.4.7.7 End User
      • 5.4.7.8 Stage
      • 5.4.7.9 Deployment
      • 5.4.7.10 Functionality
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Component
      • 5.5.1.6 Application
      • 5.5.1.7 End User
      • 5.5.1.8 Stage
      • 5.5.1.9 Deployment
      • 5.5.1.10 Functionality
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Component
      • 5.5.2.6 Application
      • 5.5.2.7 End User
      • 5.5.2.8 Stage
      • 5.5.2.9 Deployment
      • 5.5.2.10 Functionality
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Component
      • 5.5.3.6 Application
      • 5.5.3.7 End User
      • 5.5.3.8 Stage
      • 5.5.3.9 Deployment
      • 5.5.3.10 Functionality
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Component
      • 5.5.4.6 Application
      • 5.5.4.7 End User
      • 5.5.4.8 Stage
      • 5.5.4.9 Deployment
      • 5.5.4.10 Functionality
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Component
      • 5.5.5.6 Application
      • 5.5.5.7 End User
      • 5.5.5.8 Stage
      • 5.5.5.9 Deployment
      • 5.5.5.10 Functionality
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Component
      • 5.5.6.6 Application
      • 5.5.6.7 End User
      • 5.5.6.8 Stage
      • 5.5.6.9 Deployment
      • 5.5.6.10 Functionality
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Component
      • 5.6.1.6 Application
      • 5.6.1.7 End User
      • 5.6.1.8 Stage
      • 5.6.1.9 Deployment
      • 5.6.1.10 Functionality
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Component
      • 5.6.2.6 Application
      • 5.6.2.7 End User
      • 5.6.2.8 Stage
      • 5.6.2.9 Deployment
      • 5.6.2.10 Functionality
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Component
      • 5.6.3.6 Application
      • 5.6.3.7 End User
      • 5.6.3.8 Stage
      • 5.6.3.9 Deployment
      • 5.6.3.10 Functionality
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Component
      • 5.6.4.6 Application
      • 5.6.4.7 End User
      • 5.6.4.8 Stage
      • 5.6.4.9 Deployment
      • 5.6.4.10 Functionality
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Component
      • 5.6.5.6 Application
      • 5.6.5.7 End User
      • 5.6.5.8 Stage
      • 5.6.5.9 Deployment
      • 5.6.5.10 Functionality

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Benevolent AI
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Exscientia
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Atomwise
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Insilico Medicine
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Recursion Pharmaceuticals
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Xtal Pi
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Valo Health
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Cyclica
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Deep Genomics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Healx
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Bio Symetrics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Schrodinger
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Verge Genomics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Peptilogics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Revive Med
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Two XAR
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Numerate
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Inveni AI
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Owkin
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Lantern Pharma
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us